- Secukinumab in the treatment of psoriasis2016 | Third Faculty of Medicine
- Secukinumab in treating psoriatic arthritis2017 | First Faculty of Medicine
- Multidomain efficacy of secukinumab in psoriatic arthritis2023 | First Faculty of Medicine
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (Clinical trial IMMerge)2020 | Faculty of Medicine in Pilsen
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial2020 | Faculty of Medicine in Pilsen
- Psoriasis in difficult-to-treat areas - successful treatment with secukinumab2019 | Third Faculty of Medicine
- Secukinumab v dlouhodobé léčbě axiálních spondyloartritid2018 | Publication without faculty affiliation
- Research Report University Hospital for clinical assessment CAIN457A2304E1Publication without faculty affiliation
- Long‑term effect and safety of secukinumab in the therapy of ankylosing spondylitis – a case study2023 | First Faculty of Medicine
- Commentary to the study2019 | Faculty of Medicine in Hradec Králové
- Úspěšná léčba generalizované psoriázy secukinumabem2017 | First Faculty of Medicine
- The safety of secukinumab in treating psoriasis2017 | Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CAIN457A2304E1Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CAIN457A2304Publication without faculty affiliation
- Secukinumab in the treatment of ankylosing spondylitis2019 | First Faculty of Medicine
- Secukinumab in the therapy of psoriatic arthritis - safety and quality of life in patients2017 | First Faculty of Medicine
- Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study2020 | First Faculty of Medicine
- Real-world Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients with Psoriatic Arthritis in Thirteen European Countries2022 | First Faculty of Medicine
- Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry2019 | First Faculty of Medicine, Central Library of Charles University
- Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial2019 | Third Faculty of Medicine
- Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study2016 | First Faculty of Medicine
- Léčba secukinumabem u pacienta se souběhem těžké formy psoriázy a roztroušené sklerózy2019 | Third Faculty of Medicine
- Inhibition of IL-17 - a new approach in the biological treatment of spondyloarthritides2017 | First Faculty of Medicine
- Invasive aspergillus infection of middle ear in a patient treated with secukinumab, methotrexate and corticosteroids for psoriasis and psoriatic arthritis2022 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Analýza pacientů na terapii secukinumabem na Dermatovenerologické klinice 3. LF UK a FNKV Praha2019 | Third Faculty of Medicine
- Highly active form of psoriatic arthritis on top of pemphigus vulgaris and its successful treatment with secukinumab2018 | First Faculty of Medicine
- A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis2021 | First Faculty of Medicine
- Úspěšná léčba kožních projevů psoriázy secukinumabem indikovaným v terapii aktivní formy ankylozující spondylitidy2018 | Publication without faculty affiliation
- Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab2022 | Second Faculty of Medicine
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | First Faculty of Medicine, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen